BCRX vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals significant concerns with a weak Piotroski F-Score of 2/9, indicating poor financial health, and an absent Altman Z-Score, preventing a clear distress risk assessment. Despite this, the company shows strong revenue growth of 36.1% YoY, improving operating margins, and a bullish analyst consensus of 'strong_buy' with a $20.50 target price. However, negative profit margin, insider selling, and lack of key valuation metrics like Graham Number and Altman Z-Score create substantial uncertainty. The stock trades well below its target, suggesting potential upside, but fundamental weaknesses and mixed earnings performance temper optimism.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BCRX vs JNJ: Head-to-Head Comparison
This page compares BioCryst Pharmaceuticals, Inc. (BCRX) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.